$EW (Edwards Lifesciences Corp.)

$EW {{ '2016-02-02T21:58:22+0000' | timeago}} • Announcement

$EW said Transcatheter Heart Valve Therapy (THV) sales for 4Q15 rose 25% to $334.3MM, or $329.8MM and 32.4% percent growth on an underlying basis. Global sales were led by the impact of the SAPIEN 3 valve in the U.S. and double-digit underlying sales growth across all regions, the company said.

$EW {{ '2017-07-26T20:43:20+0000' | timeago}} • Announcement

For 3Q17, $EW projects underlying sales, adjusting for the impact of Germany stocking sales consumption, to be between $810-850MM, and adjusted earnings per share of $0.80 to $0.90.

$EW {{ '2017-07-26T20:42:56+0000' | timeago}} • Announcement

For FY17, $EW's full year sales estimate is now at the high end of its previous $3.2-3.4Bil guidance. Edwards Lifesciences Corp is also raising its estimate for FY17 adjusted earnings per share to $3.65-3.85, from $3.43-3.55.

$EW {{ '2017-07-26T20:40:21+0000' | timeago}} • Announcement

With strong demand for TAVR therapy resulted in total sales growth of 15% on an underlying basis, $EW's 2Q17 sales soared 11% to $841.8MM. Net income for the quarter jumped 47% to $186.1MM or $0.86 per diluted share. Adjusted earnings per share grew 42.1% to $1.08 while underlying sales rose 15% to about $864MM.

$EW {{ '2017-04-25T23:07:05+0000' | timeago}} • Webcast

In terms of the enrollment for low risk trial PARTNER III, $EW said it had a slow start in 2016, but is hopeful to get fully enrolled by the end of 2017.

$EW {{ '2017-04-25T21:11:05+0000' | timeago}} • Announcement

$EW expects its 2Q17 sales, excluding the impact of Germany stocking sales, to be about $810-850MM. Adjusted EPS is expected to be about $0.82-0.92.

$EW {{ '2017-04-25T21:09:18+0000' | timeago}} • Announcement

For FY17, $EW is narrowing its sales guidance to $3.2-3.2MM, from $3.0-3.4Bil. The company also raised its guidance for adjusted EPS to $3.43-3.55, from $3.30-3.45.

$EW {{ '2017-04-25T21:04:16+0000' | timeago}} • Announcement

Medical device maker $EW 1Q17 earnings rose 61% to $230.2MM or $1.06 per share, compared to $143MM, or $0.66 per share during 1Q16. Sales rose 26.7% YoY to $883.5MM. Excluding items, $EW earned $0.94, up 32%.

$PSA {{ '2017-02-23T13:58:17+0000' | timeago}} • Announcement

$PSA has appointed Leslie Heisz as an independent trustee of its Board of Trustees, effective February 23, 2017. Heisz's appointment expands the board to nine trustees, six of whom are independent. She currently serves on the boards of Kaiser Permanente and $EW.

$EW {{ '2017-02-02T00:00:03+0000' | timeago}} • Webcast

For 2017, $EW expects Transcatheter Heart Valve Therapy sales of $1.7-2Bil. For Surgical Heart Valve Therapy, the company expects sales of $750-790MM and for Critical Care, sales are expected to be $560-600MM.

$EW {{ '2017-02-01T23:48:47+0000' | timeago}} • Webcast

In 4Q16, $EW’s Critical Care sales were $146.3MM, representing an increase of 4.1% versus last year, or 2.5% on an underlying basis. Growth was driven by its Enhanced Surgical Recovery Program in the US and developing markets. In 2017, $EW expects underlying sales growth for Critical Care to be 5-7%.

$EW {{ '2017-02-01T23:45:27+0000' | timeago}} • Webcast

$EW's Surgical Heart Valve Therapy sales for 4Q16 were $189MM, down 4% compared to last year, driven by lower aortic valve sales in the US and Europe. Surgical heart valve sales were lower, primarily due to the impact of SAPIEN 3 and continued constrained mitral supply.

$EW {{ '2017-02-01T23:37:13+0000' | timeago}} • Webcast

During 4Q16, $EW’s Transcatheter Heart Valve sales in the US were $267MM and grew 41% on an underlying basis versus the prior year. Outside the US, underlying THV sales grew 19%. The company estimates total TAVR procedure growth in Europe was approx. 15% in 4Q16 compared to last year.

$EW {{ '2017-02-01T22:17:31+0000' | timeago}} • Announcement

$EW still expects 2017 sales of $3.0-3.4Bil and adjusted EPS of $3.30-3.45. For 1Q17, $EW expects sales of $760-800MM and adjusted EPS of $0.79-0.89.

$EW {{ '2017-02-01T22:15:49+0000' | timeago}} • Announcement

$EW's Transcatheter Heart Valve Therapy (THVT) sales for 4Q16 was $432MM, a 29.2% growth rate over 4Q15, or 31.8% on an underlying basis. Growth was led by continued strong therapy adoption across all geographies, with notable strength in the U.S. and Japan.

$EW {{ '2017-02-01T22:15:32+0000' | timeago}} • Announcement

$EW reported a rise in 4Q16 earnings driven by higher sales and strong adoption of transcatheter aortic valve replacement (TAVR) therapy. Net income rose to $158.5MM or $0.73 per share from $140.7MM or $0.64 per share last year. Net sales grew to $767.7MM from $671.1MM. Adjusted EPS increased to $0.75 from $0.64.

$EW {{ '2016-10-25T22:39:42+0000' | timeago}} • Webcast

During 3Q16, $EW generated free cash flow of $158MM. This is defined as cash flow from operating activities of $206MM, less capital investments of $48MM. At the end of 3Q16, the company had cash, cash equivalents and short-term investments of approx. $1.2Bil. Total debt was approx. $600MM.

$EW {{ '2016-10-25T22:35:34+0000' | timeago}} • Webcast

$EW continues to expect SG&A, excluding special items, to be between 30-32% of sales for the full year 2016. The company has increased investments in structural heart initiatives with the benefit of this year's medical device excise tax suspension. R&D investments in 3Q16 grew 12% over the prior year to $113MM or 15.3% of sales.

$EW {{ '2016-10-25T22:20:20+0000' | timeago}} • Webcast

In Europe, $EW saw strong procedure growth across the majority of countries. The company estimates total procedures grew around 20% in 3Q16 compared to last year, however its growth rate was lower mainly due to reduced selling in France.

$EW {{ '2016-10-25T22:19:04+0000' | timeago}} • Webcast

Outside of the US, $EW said underlying THV sales grew 15%. The company continues to be encouraged by the strong adoption of Transcatheter Aortic Valve Replacement in Japan with the rollout of Sapien 3 expected to be completed during 4Q16.

$EW {{ '2016-10-25T22:10:57+0000' | timeago}} • Announcement

$EW raised its FY16 adjusted EPS guidance to $2.82-2.92 from prior estimate of $2.78-2.88. $EW still expects 2016 sales to be at high end of its prior $2.7-3Bil range, based on strong year-to-date results, and momentum of therapy adoption globally. For 4Q16, $EW sees sales of $750-790MM and adjusted EPS of $0.67-0.77.

Recent Transcripts

JCI (Johnson Controls Inc.)
Thursday, July 27 2017 - 3:00pm
SNN (Smith & Nephew plc)
Thursday, July 27 2017 - 8:00am
EW (Edwards Lifesciences Corp.)
Wednesday, July 26 2017 - 9:00pm
MMSI (Merit Medical Systems, Inc.)
Wednesday, July 26 2017 - 9:00pm
CNMD (CONMED Corporation)
Wednesday, July 26 2017 - 8:30pm
BABY (Natus Medical Inc.)
Wednesday, July 26 2017 - 3:00pm
CHE (Chemed Corp.)
Wednesday, July 26 2017 - 2:00pm
IART (Integra LifeSciences Holdings Corporation)
Wednesday, July 26 2017 - 12:30pm
CRY (CryoLife Inc.)
Tuesday, July 25 2017 - 12:00pm
ISRG (Intuitive Surgical, Inc.)
Thursday, July 20 2017 - 8:30pm
PII (Polaris Industries Inc.)
Thursday, July 20 2017 - 2:00pm
MDT (Medtronic plc)
Thursday, May 25 2017 - 12:00pm
ACAD (ACADIA Pharmaceuticals Inc.)
Tuesday, May 9 2017 - 9:00pm
STE (Steris Plc)
Tuesday, May 9 2017 - 2:00pm
XRAY (DENTSPLY International Inc.)
Tuesday, May 9 2017 - 12:30pm
ENDP (Endo International plc)
Tuesday, May 9 2017 - 12:30pm
IVC (Invacare Corporation)
Tuesday, May 9 2017 - 12:30pm
SNN (Smith & Nephew plc)
Friday, May 5 2017 - 7:30pm
SYN (Synthetic Biologics Inc.)
Thursday, May 4 2017 - 8:30pm
KAMN (Kaman Corporation)
Thursday, May 4 2017 - 12:30pm

AlphaGraphics you may like